Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03835949 |
Recruitment Status :
Active, not recruiting
First Posted : February 11, 2019
Last Update Posted : April 1, 2022
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Solid Tumor Metastatic Cancer | Drug: TJ004309 Drug: Atezolizumab | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 36 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1 Dose-Escalation Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer |
Actual Study Start Date : | July 16, 2019 |
Estimated Primary Completion Date : | June 2022 |
Estimated Study Completion Date : | June 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: TJ004309 plus Atezolizumab
TJ004309 will be dose escalated in a 3+3 design in combination with atezolizumab.
|
Drug: TJ004309
Antibody to CD73 Drug: Atezolizumab Humanized monoclonal antibody to PD-L1 |
- Maximum Tolerate Dose of TJ004309 plus Atezolizumab [ Time Frame: Approximately 2-8 months ]Evaluate safety and tolerability and determine a recommended Phase 2 dose of TJ004309 when combined with standard dose atezolizumab in patients with advanced or metastatic cancer. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 and coded using MedDRA 14.1.
- Determine Phase 2 dose to TJ004309 as a single agent [ Time Frame: Approximately 2-8 months ]Determine the Phase 2 dose of TJ004309 as a single agent
- Trough TJ004309 concentrations [ Time Frame: Approximately 2-8 months ]Trough (pre-dose and post-dose) serum TJ004309 concentrations will be measured when given as a single agent and with atezolizumab
- Trough atezolizumab concentrations [ Time Frame: Approximately 2-8 months ]Trough (pre-dose and post-dose) serum atezolizumab concentrations will be measured when given with TJ004309
- Determine the Rate of TJ004309 Immunogenicity [ Time Frame: Approximately 2-8 months ]The number of patients who develop immunogenicity to TJ004309 (anti-product antibody development) will be determined.
- Determine the Rate of Atezolizumab Immunogenicity [ Time Frame: Approximately 2-8 months ]The number of patients who develop immunogenicity to atezolizumab (anti-product antibody development) will be determined.
- Assessment of antitumor activity [ Time Frame: Approximately 2-8 months ]Antitumor activity will be assessed by the response rate by iRECIST and RECIST 1.1

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically confirmed advanced or metastatic cancer in patients who are refractory to or intolerant to all available therapy.
- Measurable disease by iRECIST
- Formalin fixed, paraffin-embedded (FFPE) tumor tissue that permits the preparation of 12 unstained slides of tumor sample- Biopsy must be excisional, incisional, or core. Needle aspiration is insufficient.
- Age ≥ 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
- Resolution of all acute adverse events resulting from prior cancer therapies to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade ≤ 1 or baseline (except alopecia or neuropathy)
- Adequate organ function
- Willingness and ability to consent for self to participate in study
- Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
Exclusion Criteria:
- Autoimmune disease requiring treatment within the past twelve months
- Condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days prior to study treatment
- History of or active interstitial lung disease
- Prior T-cell or NK cell therapy
- Current treatment on another therapeutic clinical trial
- Receipt of systemic anticancer therapy, including investigational agents, within 28 days prior to study treatment
- Major surgical procedure or significant traumatic injury within 4 weeks prior to study treatment, and must have fully recovered from any such procedure; and no date of surgery (if applicable) or anticipated need for a major surgical procedure planned within the next 6 months
- Chest radiotherapy ≤ 28 days, wide field radiotherapy ≤ 28 days (defined as > 50% of volume of pelvic bones or equivalent), or limited field radiation for palliation ≤ 14 days prior to study treatment - such patients must have recovered adequately from any side effects of such therapy.
- Hypertension defined as blood pressure (BP) systolic > 150 or diastolic > 90 mm Hg
- Ascites or pericardial effusion that required intervention within 3 months prior to study treatment.
- Brain involvement with cancer, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease, unless the lesion(s) have been radiated or resected, are considered fully treated and inactive, are asymptomatic, and no steroids have been administered for CNS disease over the 7 days prior to study treatment
- Angina, myocardial infarction (MI), symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack TIA), arterial embolism, pulmonary embolism, percutaneous transluminal coronary angioplasty (PTCA), or coronary artery bypass grafting (CABG) within 6 months prior to study treatment
- Thrombolytic use (except to maintain IV catheters) within 10 days prior study treatment
- Known active viral or nonviral hepatitis or cirrhosis, except patients with Hepatitis C infection and undetectable virus following treatment are eligible.
- Any active infection requiring systemic treatment
- History of hemorrhage or hemoptysis (> ½ teaspoon bright red blood) within 3 months prior to study treatment
- Known human immunodeficiency virus (HIV) unless CD4+ T cell count > 350 cells/μL with an undetectable viral load.
- Pregnancy or breastfeeding - Female patients must be surgically sterile (i.e., ≥ 6 weeks following surgical bilateral oophorectomy with or without hysterectomy or tubal ligation) or be postmenopausal for at least one year, or must agree to use effective contraception during the study and for 5 months following last dose of TJ004309. All female patients of reproductive potential must have a negative pregnancy test (serum or urine) within 7 days prior to study treatment. Male patients must be surgically sterile or must agree to use effective contraception during the study and for 5 months following last dose of TJ004309.
- Patients with any severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infections should not be enrolled in the trial. Patients who required IV antibiotics or were treated with antiviral medications within this 4 week period should be discussed with the TRACON prior to enrollment.
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for this study

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03835949
United States, Alabama | |
The University of Alabama at Birmingham | |
Birmingham, Alabama, United States, 35294 | |
United States, Arizona | |
HonorHealth Research Institute | |
Scottsdale, Arizona, United States, 85258 | |
United States, California | |
City of Hope | |
Duarte, California, United States, 91010 | |
United States, Texas | |
MD Anderson Cancer Center | |
Houston, Texas, United States, 77230 |
Study Director: | Charles Theuer, MD, PhD | Medical Monitor |
Responsible Party: | Tracon Pharmaceuticals Inc. |
ClinicalTrials.gov Identifier: | NCT03835949 |
Other Study ID Numbers: |
4309ST101 |
First Posted: | February 11, 2019 Key Record Dates |
Last Update Posted: | April 1, 2022 |
Last Verified: | March 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Neoplasm Metastasis Neoplasms Neoplasms, Second Primary Neoplastic Processes |
Pathologic Processes Atezolizumab Antineoplastic Agents |